Jacobio Pharmaceuticals Group (1167) H1 2025 earnings summary

Executive summary

• Revenue reached RMB45.7 million for the six months ended June 30, 2025, driven by a milestone payment from the Allist Licensing Agreement, compared to nil in the prior year period.

• Loss for the period narrowed significantly to RMB59.0 million from RMB169.1 million year-over-year, reflecting reduced R&D and administrative expenses.

• Major clinical milestone: glecirasib received NMPA approval and was launched in May 2025 for ≥2L NSCLC with KRAS G12C mutations, supported by strong clinical data.

• Advanced multiple clinical and preclinical oncology programs, including pan-KRAS, p53, BET, Aurora kinase A inhibitors, SHP2, and iADC/tADC platforms, with global and China-based studies ongoing.

• Entered a licensing agreement with Allist for commercialization and clinical development of glecirasib and sitneprotafib in Greater China, triggering milestone revenue.

Financial highlights

• Revenue increased by RMB45.7 million year-over-year due to the Allist Licensing Agreement milestone.

• R&D expenses decreased 47.3% to RMB93.2 million, mainly due to the absence of large pivotal trial costs, now funded by Allist.

• Administrative expenses fell 12.4% to RMB18.6 million, reflecting cost controls and efficiency gains.

• Gross profit was RMB45.7 million, up from nil in the prior year, with no cost of revenue recognized.

• Net cash used in operating activities was RMB143.1 million, a reduction from RMB180.4 million in the prior year.

Outlook and guidance

• Focus remains on advancing the KRAS and iADC pipelines, leveraging allosteric inhibitor and iADC platforms for global leadership in oncology.

• Ongoing development of pan-KRAS, tADC, and iADC programs, with key clinical readouts expected in 2026.

• Expects to utilize remaining IPO proceeds by end of 2025, with resource reallocation to early-stage drug discovery and development.

• Intends to expand global collaborations and pursue regulatory approvals in major markets.